TAVI Today: Current Evidence Across All Risk Groups<\/p>\n
Following the recently published 10-year PARTNER 2 results, the current evidence can be summarized as follows:<\/p>\n
\u2022\u2060 \u2060High-Risk\/Inoperable Patients: TAVI is an established alternative to surgery.
\n\u2022\u2060 \u2060Intermediate-Risk Symptomatic AS (PARTNER 2): Modern TAVI matches SAVR at 10 years.
\n\u2022\u2060 \u2060Low-Risk Symptomatic AS (PARTNER 3 & Evolut Low Risk): Excellent outcomes through 7\u20138 years; 10-year durability data are awaited.
\n\u2022\u2060 \u2060Asymptomatic Severe AS (EARLY TAVR): Early TAVR improves 5-year clinical outcomes versus watchful waiting.<\/p>\n
Take-Home Message
\nModern TAVI has evolved from a treatment for inoperable patients to the preferred therapy for many elderly patients with severe aortic stenosis. Current evidence supports TAVI as a durable lifetime solution for most patients aged \u226580 years. Whether the same benefit extends to younger, low-risk patients will depend on the ongoing 10-year follow-up of the PARTNER 3 and Evolut Low Risk trials.<\/p>\n
Choosing Between TAVR and SAVR :
\nComprehensive Heart Team Assessment Beyond the STS Score
\n\u2022\u2060 \u2060STS surgical risk score
\n\u2022\u2060 \u2060Life expectancy
\n\u2022\u2060 \u2060Bicuspid vs tricuspid aortic valve
\n\u2022\u2060 \u2060Coronary anatomy and future coronary access
\n\u2022\u2060 \u2060Need for concomitant cardiac surgery
\n\u2022\u2060 \u2060CT anatomical suitability
\n\u2022\u2060 \u2060Patient preference and Heart Team discussion<\/p>\n